MX2007003428A - Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa. - Google Patents

Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa.

Info

Publication number
MX2007003428A
MX2007003428A MX2007003428A MX2007003428A MX2007003428A MX 2007003428 A MX2007003428 A MX 2007003428A MX 2007003428 A MX2007003428 A MX 2007003428A MX 2007003428 A MX2007003428 A MX 2007003428A MX 2007003428 A MX2007003428 A MX 2007003428A
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
ppar
novel pyrimidine
treating
alpha modulators
Prior art date
Application number
MX2007003428A
Other languages
English (en)
Inventor
Axel Kretschmer
Stephan Bartel
Hilmar Bischoff
Klemens Lustig
Marcus Bauser
Armin Kern
Ulrich Rosentreter
Lars Barfacker
Dieter Lang
Martin Raabe
Peter Ellinghaus
Elike Dittrich-Wengenroth
Claudia Hirth-Dietrich
Christian Pilger
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MX2007003428A publication Critical patent/MX2007003428A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invencion se refiere a nuevos derivados de pirimidina, a procedimientos para su preparacion, a su uso para el tratamiento y/o la profilaxis de enfermedades, asi como a su uso para la preparacion de medicamentos para el tratamiento y/o la profilaxis de enfermedades, preferentemente para el tratamiento y/o la prevencion de enfermedades cardiovasculares, en particular, dislipidemias, arteriosclerosis, insuficiencia cardiaca, trombosis y sindrome metabolico.
MX2007003428A 2004-09-25 2005-09-10 Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa. MX2007003428A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004046623A DE102004046623A1 (de) 2004-09-25 2004-09-25 Neue Pyrimidin-Derivate und ihre Verwendung
PCT/EP2005/009734 WO2006032384A1 (de) 2004-09-25 2005-09-10 Neue pyrimidin-derivate und ihre verwendung als ppar-alpha-modulatoren

Publications (1)

Publication Number Publication Date
MX2007003428A true MX2007003428A (es) 2008-03-13

Family

ID=35063041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003428A MX2007003428A (es) 2004-09-25 2005-09-10 Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa.

Country Status (22)

Country Link
US (1) US20080261990A1 (es)
EP (1) EP1797045A1 (es)
JP (1) JP2008514559A (es)
KR (1) KR20070055621A (es)
CN (1) CN101065364A (es)
AR (1) AR051295A1 (es)
AU (1) AU2005287589A1 (es)
BR (1) BRPI0517327A (es)
CA (1) CA2582492A1 (es)
DE (1) DE102004046623A1 (es)
EC (1) ECSP077340A (es)
GT (1) GT200500266A (es)
IL (1) IL182136A0 (es)
MA (1) MA28882B1 (es)
MX (1) MX2007003428A (es)
NO (1) NO20072051L (es)
PE (1) PE20060657A1 (es)
RU (1) RU2007115215A (es)
SV (1) SV2007002235A (es)
TW (1) TW200628451A (es)
UY (1) UY29127A1 (es)
WO (1) WO2006032384A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2591783A1 (en) * 2007-04-13 2013-05-15 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
KR100813387B1 (ko) * 2007-06-26 2008-03-12 신명곤 부형제 첨가없이 인삼농축액으로 유동성 및 저장성이우수한 인삼농축액환 제조 방법
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
KR101898610B1 (ko) 2010-08-31 2018-09-14 서울대학교산학협력단 ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도
CN107375932B (zh) 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
EA029581B1 (ru) 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
EP2968262A1 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
WO2017190050A1 (en) * 2016-04-28 2017-11-02 Cornell University Inhibitors of soluble adenylyl cyclase
MX2021009622A (es) 2019-02-12 2021-11-04 Mirum Pharmaceuticals Inc Metodos para tratar la colestasis.
CN115598267B (zh) * 2022-12-13 2023-05-09 山东省食品药品检验研究院 一种格列齐特中潜在遗传毒性杂质的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177187B1 (en) * 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
GB0214254D0 (en) * 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CA2582492A1 (en) 2006-03-30
SV2007002235A (es) 2007-03-20
BRPI0517327A (pt) 2008-10-07
US20080261990A1 (en) 2008-10-23
AR051295A1 (es) 2007-01-03
EP1797045A1 (de) 2007-06-20
MA28882B1 (fr) 2007-09-03
ECSP077340A (es) 2007-04-26
PE20060657A1 (es) 2006-08-12
GT200500266A (es) 2006-05-11
RU2007115215A (ru) 2008-11-10
UY29127A1 (es) 2006-04-28
WO2006032384A1 (de) 2006-03-30
NO20072051L (no) 2007-06-07
TW200628451A (en) 2006-08-16
KR20070055621A (ko) 2007-05-30
AU2005287589A1 (en) 2006-03-30
JP2008514559A (ja) 2008-05-08
IL182136A0 (en) 2007-07-24
CN101065364A (zh) 2007-10-31
DE102004046623A1 (de) 2006-03-30

Similar Documents

Publication Publication Date Title
MX2007003428A (es) Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa.
MX2010002565A (es) Acidos 6-fenilnicotinicos substituidos y su uso.
ECSP077357A (es) Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil) fenil] amino}carbonil)amino]fenoxi}n-metilpiridina-2-carboxamida
TW200736213A (en) Dicarboxylic acid derivatives and their use
TW200621765A (en) Substituted phenylaminothiazoles and their use
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
JO2756B1 (en) The second preparation of aqueous pyrimidnon containing 4- (4-ciano-2-2 thiourail) and its use)
MY169980A (en) Bisaryl-linked aryltriazolones and their use
PL381801A1 (pl) Pochodne mocznika, kompozycje zawierające pochodne mocznika oraz zastosowanie pochodnych mocznika do wytwarzania leku do leczenia skurczowej niewydolności serca
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MX2007005039A (es) Formulacion de tableta estable.
WO2006008028A8 (de) Neue 6-formyl-tetrahydropteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel, u.a. gegen krebs
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
ATE530526T1 (de) Lactam-substituierte dicarbonsäuren und ihre verwendung
TW200724532A (en) Pyrimidinecarboxylic acid derivatives and their use
TW200700064A (en) Novel compounds
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
NZ552328A (en) Arylsulphonylstilbene derivatives for treatment of insomnia and related conditions
UA94080C2 (ru) Ациклически-замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
PT1745010E (pt) Derivados de ciclo-hexil-1,4-diamina substituídos
WO2008031501A3 (de) 2-phenoxynikotinsäure-derivate und ihre verwendung
ATE399175T1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
WO2008131859A3 (de) Verwendimg cyclisch substituierter furopyrimidin-derivate zur behandlung der pulmonalen arteriellen hypertonie

Legal Events

Date Code Title Description
FA Abandonment or withdrawal